APA (7th ed.) Citation

Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Szczylik, C., . . . Kennedy, D. (2025). Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: Final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet, 406(10502), 447. https://doi.org/10.1016/S0140-6736(25)00684-1

Chicago Style (17th ed.) Citation

Agarwal, Neeraj, et al. "Talazoparib Plus Enzalutamide in Men with Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Results from the Randomised, Placebo-controlled, Phase 3 TALAPRO-2 Trial." Lancet 406, no. 10502 (2025): 447. https://doi.org/10.1016/S0140-6736(25)00684-1.

MLA (9th ed.) Citation

Agarwal, Neeraj, et al. "Talazoparib Plus Enzalutamide in Men with Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Results from the Randomised, Placebo-controlled, Phase 3 TALAPRO-2 Trial." Lancet, vol. 406, no. 10502, 2025, p. 447, https://doi.org/10.1016/S0140-6736(25)00684-1.